首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1535673

碳青黴烯市場 - 按藥物類別（美羅培南、亞胺培南、厄他培南、多尼培南）、應用（泌尿道、血液和腹內感染、細菌性腦膜炎）、配銷通路- 全球預測（2024 - 2032）

Carbapenem Market - By Drug Class (Meropenem, Imipenem, Ertapenem, Doripenem), Application (Urinary Tract, Bloodstream, & Intra-Abdominal Infections, Bacterial Meningitis), Distribution Channel - Global Forecast (2024 - 2032)

出版日期: 2024年06月12日 | 出版商:

Global Market Insights Inc. | 英文 167 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在不斷成長的醫療保健需求的推動下，全球碳青黴烯市場預計從 2024 年到 2032 年將實現 5% 的複合年成長率。世界衛生組織(WHO) 報告稱，到2050 年，全球60 歲及以上人口預計將增加近一倍，從2015 年的12% 增至22%。中等收入國家。人口老化更容易患慢性病和感染，增加了對碳青黴烯類等有效抗生素的需求。

此外，院內感染的高盛行率進一步促進了市場成長，因為碳青黴烯類藥物經常用於治療嚴重的院內感染。

整個碳青黴烯類市場根據藥物類別、應用、配銷通路和區域進行細分。

亞胺培南細分市場將在 2024 年至 2032 年期間經歷大幅成長。製藥公司正專注於此類藥物來解決嚴重的細菌感染。亞胺培南的廣譜活性和抗抗藥性菌株的功效使其對於治療危及生命的疾病至關重要。增強的生產能力和嚴格的監管合規性確保了高品質的亞胺培南供應，滿足醫療機構對強效抗生素不斷成長的需求。

到 2032 年，血流感染應用領域將佔據重要的碳青黴烯類市場。碳青黴烯類，包括亞胺培南，由於其廣譜抗菌特性，在控制這些感染方面發揮關鍵作用。血流感染盛行率的增加，特別是在醫院環境中，推動了碳青黴烯類藥物的採用。診斷技術和醫療基礎設施的進步透過實現及時、準確的感染管理進一步支持市場成長。

由於快速城市化、醫療支出增加和傳染病高發，亞太地區碳青黴烯類市場將在 2024 年至 2032 年期間實現可觀的成長。完善的醫療保健系統、對醫學研究的大量投資以及健全的監管框架確保了藥品的品質和安全。政府對醫療保健計劃的支持以及該地區領先製藥公司的存在推動了創新和生產，促進了亞太地區碳青黴烯市場的強勁成長。

產業生態系統分析
產業影響力
- 成長動力
  - 抗生素抗藥性感染的盛行率不斷增加
  - 臨床研究的高研發投資
  - 院內感染發生率不斷上升
  - 提高認知和診斷進步
- 產業陷阱與挑戰
  - 碳青黴烯類抗生素生產成本高
  - 副作用和安全問題
成長潛力分析
監管環境
技術景觀
- 核心技術
- 鄰近技術
2023 年定價分析
- 按地區
- 按關鍵人物
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
美羅培南
亞胺培南
厄他培南
多尼培南
其他藥物類別

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
泌尿道感染
血流感染
腹腔內感染
細菌性腦膜炎
其他應用

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AstraZeneca PLC
Aurobindo Pharma
Daewoong Pharmaceuticals Co., Ltd.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Kopran Limited
Lupin Limited
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Shenzhen Haibin Pharmaceutical Co. Ltd.
Sun Pharmaceutical Industries Ltd.
The Menarini Group
Venus Remedies Ltd.
Viatris Inc.

簡介目錄

Product Code: 9836

Global Carbapenem Market is set to achieve a 5% CAGR from 2024 to 2032, driven by increasing healthcare demands. The World Health Organization (WHO) reports that the global population aged 60 and above is projected to nearly double from 12% in 2015 to 22% by 2050. By then, 80% of older individuals will reside in low- and middle-income countries. This aging demographic is more prone to chronic conditions and infections, escalating the need for effective antibiotics such as carbapenems.

In addition, the high prevalence of Hospital-Acquired Infections further contributes to the market growth as Carbapenems are often used to treat severe hospital-acquired infections.

The overall Carbapenem Market is segmented based on drug class, application, distribution channel, and region.

The Imipenem segment will experience substantial growth over 2024-2032. Pharmaceutical companies are focusing on this drug class to address severe bacterial infections. Imipenem's broad-spectrum activity and efficacy against resistant strains make it crucial in treating life-threatening conditions. Enhanced production capabilities and stringent regulatory compliance ensure high-quality imipenem supply, meeting the rising demand for potent antibiotics in healthcare settings.

The Bloodstream infections application segment will capture a significant Carbapenem market share by 2032. Bloodstream infections require immediate and effective treatment to prevent severe complications and mortality. Carbapenems, including imipenem, play a critical role in managing these infections due to their broad-spectrum antibacterial properties. Increased prevalence of bloodstream infections, particularly in hospital settings, drives the adoption of carbapenems. Advances in diagnostic technologies and healthcare infrastructure further support market growth by enabling timely and accurate infection management.

Asia Pacific carbapenem market will drive commendable gains throughout 2024-2032 due to rapid urbanization, increasing healthcare expenditures, and a high prevalence of infectious diseases. Well-established healthcare systems, significant investment in medical research, and robust regulatory frameworks ensure the quality and safety of pharmaceutical products. Government support for healthcare initiatives and the presence of leading pharmaceutical companies in the region drive innovation and production, contributing to the strong growth of the carbapenem market in Asia Pacific.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of antibiotic-resistant infections
  - 3.2.1.2 High R&D investments in clinical research
  - 3.2.1.3 Growing incidence of hospital-acquired infections
  - 3.2.1.4 Increased awareness and diagnostic advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of production of carbapenem-based antibiotics
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Meropenem
5.3 Imipenem
5.4 Ertapenem
5.5 Doripenem
5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Urinary tract infections
6.3 Bloodstream infections
6.4 Intra-abdominal infections
6.5 Bacterial meningitis
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa